Company: DVAX
Filing Date: 2025-04-15
Form Type: PRER14A
Source: 0000930413-25-001254
Chunk: 103

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-15
Form: PRER14A
Chunk 103
---
, subject to stockholder approval, to implement
this significant governance change over a three-year period to enable a smooth transition. For additional information regarding this governance
change, please see “Proposal No. 4:To amend and restate the Company’s Restated Certificate of Incorporation to provide
for the declassification of the Company’s Board of Directors on a phased basis and to implement certain other changes.” In
addition, in response to stockholder feedback, we increased the performance-linked equity to 30% of equity awards made to executives for
2023, further increased to 33% in 2024 and have enhanced our ESG disclosures immediately above.

| 84 |

<div align='center'>CERTAIN TRANSACTIONS</div>

Since January 1, 2024, there has not been, nor is there currently proposed,
any transaction or series of similar transactions to which the Company was or is to be a party in which the amount involved exceeds $120,000
and in which any current director, executive officer, holder of more than 5% of our common stock or any immediate family member of any
of the foregoing persons had or will have a direct or indirect material interest other than compensation arrangements, described under
the sections entitled “Executive Compensation” and “Director Compensation,” and with respect to the indemnification
agreements described below.

Related Persons Transactions and Indemnification

Policies and Procedures for Related Person Transactions

Our Audit Committee is responsible for reviewing and approving all
related party transactions, which would include a transaction, arrangement or relationship (or any series of similar transactions, arrangements
or relationships) in which we and any “related person” are participants involving an amount that exceeds $120,000, not including
transactions involving compensation for services provided to Dynavax as an employee, director, consultant or similar capacity by a related
person. Related parties include any of our directors or executive officers, certain of our stockholders and their immediate family members.
This obligation is set forth in writing in the Audit Committee charter. A copy of the Audit Committee charter is available on the Company’s
website at https://investors.dynavax.com/corporate-governance.

Where a transaction has been identified as a related-person transaction,
management would present information regarding the proposed related-person transaction to the Audit Committee (or, where Audit Committee
approval would be inappropriate, to another independent body of the Board) for consideration and approval or ratification. The presentation
would include a description of, among other